Iovance Biotherapeutics, Inc. (FRA:2LB)

Iovance Biotherapeutics Statistics

Total Valuation

FRA:2LB has a market cap or net worth of EUR 761.48 million. The enterprise value is 547.89 million.

Market Cap	761.48M
Enterprise Value	547.89M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	396.97M
Shares Outstanding	n/a
Shares Change (YoY)	+19.46%
Shares Change (QoQ)	+8.83%
Owned by Insiders (%)	7.38%
Owned by Institutions (%)	46.87%
Float	338.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.57
PB Ratio	1.27
P/TBV Ratio	2.14
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.62
EV / Sales	2.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.83

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.07.

Current Ratio	3.41
Quick Ratio	2.92
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -53.89% and return on invested capital (ROIC) is -31.99%.

Return on Equity (ROE)	-53.89%
Return on Assets (ROA)	-27.12%
Return on Invested Capital (ROIC)	-31.99%
Return on Capital Employed (ROCE)	-52.79%
Revenue Per Employee	254,698
Profits Per Employee	-404,418
Employee Count	838
Asset Turnover	0.26
Inventory Turnover	4.40

Taxes

Income Tax	-594,053
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-75.85%
50-Day Moving Average	1.91
200-Day Moving Average	2.31
Relative Strength Index (RSI)	53.78
Average Volume (20 Days)	2,227

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.41

Income Statement

In the last 12 months, FRA:2LB had revenue of EUR 213.44 million and -338.90 million in losses. Loss per share was -1.02.

Revenue	213.44M
Gross Profit	44.16M
Operating Income	-350.58M
Pretax Income	-339.50M
Net Income	-338.90M
EBITDA	-320.28M
EBIT	-350.58M
Loss Per Share	-1.02

Balance Sheet

The company has 256.37 million in cash and 44.74 million in debt, giving a net cash position of 211.64 million.

Cash & Cash Equivalents	256.37M
Total Debt	44.74M
Net Cash	211.64M
Net Cash Per Share	n/a
Equity (Book Value)	598.56M
Book Value Per Share	1.55
Working Capital	258.51M

Cash Flow

In the last 12 months, operating cash flow was -275.41 million and capital expenditures -24.45 million, giving a free cash flow of -299.86 million.

Operating Cash Flow	-275.41M
Capital Expenditures	-24.45M
Free Cash Flow	-299.86M
FCF Per Share	n/a

Margins

Gross margin is 20.69%, with operating and profit margins of -164.25% and -158.78%.

Gross Margin	20.69%
Operating Margin	-164.25%
Pretax Margin	-159.06%
Profit Margin	-158.78%
EBITDA Margin	-150.06%
EBIT Margin	-164.25%
FCF Margin	n/a

Dividends & Yields

FRA:2LB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.46%
Shareholder Yield	-19.46%
Earnings Yield	-44.51%
FCF Yield	-39.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2LB has an Altman Z-Score of -0.5 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.5
Piotroski F-Score	2